These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 7474300)

  • 1. A novel modified tissue-type plasminogen activator (t-PA), E6010, reduces reperfusion arrhythmias induced after coronary thrombolysis--comparison of native t-PA and urokinase.
    Saito M; Suzuki S; Yui Y; Kawai C
    Jpn Circ J; 1995 Aug; 59(8):556-64. PubMed ID: 7474300
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel modified tissue-type plasminogen activator (t-PA), E6010, gradually increases coronary blood flow after thrombolysis compared with native t-PA, urokinase and balloon catheter occlusion-reperfusion.
    Saito M; Suzuki S; Yui Y; Kawai C
    Jpn J Pharmacol; 1994 Sep; 66(1):17-23. PubMed ID: 7532243
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel modified t-PA, E-6010, induces faster recovery of ventricular function after coronary thrombolysis than native t-PA in a canine thrombosis model.
    Suzuki S; Saito M; Yui Y; Kawai C
    Jpn Circ J; 1995 Apr; 59(4):205-12. PubMed ID: 7658613
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intracoronary infusion of E6010 has more potent thrombolytic activity than tissue plasminogen activator (t-PA) in dogs: a higher plasma level of E6010 than t-PA causes potent thrombolytic activity.
    Suzuki S; Saito M; Suzuki N; Kato H; Nagaoka N; Yoshitake S; Yui Y; Kawai C
    J Cardiovasc Pharmacol; 1993 Dec; 22(6):834-40. PubMed ID: 7509901
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thrombolytic properties of a novel modified human tissue-type plasminogen activator (E6010): a bolus injection of E6010 has equivalent potency of lysing young and aged canine coronary thrombi.
    Suzuki S; Saito M; Suzuki N; Kato H; Nagaoka N; Yoshitake S; Mizuo H; Yuzuriha T; Yui Y; Kawai C
    J Cardiovasc Pharmacol; 1991 May; 17(5):738-46. PubMed ID: 1713988
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thrombolytic effects of a novel modified tissue plasminogen activator, E6010, on coronary thrombosis in the pig.
    Adachi H; Nagaoka N; Nomoto K; Yuzuriha T; Shoji T
    Jpn J Pharmacol; 1992 Mar; 58(3):309-19. PubMed ID: 1513078
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A prospective, randomized, double-blind multicenter trial of a single bolus injection of the novel modified t-PA E6010 in the treatment of acute myocardial infarction: comparison with native t-PA. E6010 Study Group.
    Kawai C; Yui Y; Hosoda S; Nobuyoshi M; Suzuki S; Sato H; Takatsu F; Motomiya T; Kanmatsuse K; Kodama K; Yabe Y; Minamino T; Kimata S; Nakashima M
    J Am Coll Cardiol; 1997 Jun; 29(7):1447-53. PubMed ID: 9180103
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of intravenous bolus injection or continuous infusion of recombinant single chain urokinase-type plasminogen activator (saruplase) for thrombolysis. A canine model of combined coronary arterial and femoral venous thrombosis.
    Rapold HJ; Wu ZM; Stassen T; Van de Werf F; Collen D
    Blood; 1990 Oct; 76(8):1558-63. PubMed ID: 2119830
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thrombolysis of canine femoral artery thrombus by a novel modified tissue-type plasminogen activator (E6010).
    Suzuki N; Suzuki S; Nagaoka N; Mizuo H; Yuzuriha T; Yoshitake S; Kanmatuse K
    Jpn J Pharmacol; 1994 Jul; 65(3):257-63. PubMed ID: 7799526
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative thrombolytic properties of tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (u-PA) and K1K2Pu (a t-PA/u-PA chimera) in a combined arterial and venous thrombosis model in the dog.
    Lu HR; Wu Z; Pauwels P; Lijnen HR; Collen D
    J Am Coll Cardiol; 1992 May; 19(6):1350-9. PubMed ID: 1342779
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative studies of thrombolysis with single-chain and two-chain recombinant tissue-type plasminogen activators in canine coronary thrombosis.
    Yokoyama M; Ichikawa Y; Yatani A; Matsui K; Nakahara H; Kaneko M; Sakurama T; Ueshima S; Matsuo O
    J Cardiovasc Pharmacol; 1996 Oct; 28(4):571-5. PubMed ID: 8891884
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [New thrombolytic agents in myocardial infarction].
    Charbonnier B; Lang M; Brochier M
    Arch Mal Coeur Vaiss; 1987 Nov; 80(12):1785-91. PubMed ID: 3128222
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heparin requirement in tissue-type plasminogen activator-induced experimental coronary thrombolysis: comparison with urokinase-induced coronary thrombolysis.
    Susawa T; Yui Y; Hattori R; Takahashi M; Aoyama T; Takatsu Y; Sakaguchi K; Yui N; Kawai C
    Jpn Circ J; 1987 Apr; 51(4):431-5. PubMed ID: 2441082
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of thrombolytic and systemic effects of the novel recombinant plasminogen activator BM 06.022 compared with alteplase, anistreplase, streptokinase and urokinase in a canine model of coronary artery thrombosis.
    Martin U; Sponer G; Strein K
    J Am Coll Cardiol; 1992 Feb; 19(2):433-40. PubMed ID: 1732372
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thrombolysis with recombinant human single-chain urokinase-type plasminogen activator (rscu-PA): dose-response in dogs with coronary artery thrombosis.
    Van de Werf F; Jang IK; Collen D
    J Cardiovasc Pharmacol; 1987 Jan; 9(1):91-3. PubMed ID: 2434801
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Experiences with pro-urokinase and potentiation of its fibrinolytic effect by urokinase and by tissue plasminogen activator.
    Gurewich V
    J Am Coll Cardiol; 1987 Nov; 10(5 Suppl B):16B-21B. PubMed ID: 3117859
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synergism of thrombolytic agents in vivo.
    Collen D; Stassen JM; Stump DC; Verstraete M
    Circulation; 1986 Oct; 74(4):838-42. PubMed ID: 3093116
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Coronary arterial thrombolysis with low-dose synergistic combinations of recombinant tissue-type plasminogen activator (rt-PA) and recombinant single-chain urokinase-type plasminogen activator (rscu-PA) for acute myocardial infarction.
    Collen D; Van de Werf F
    Am J Cardiol; 1987 Sep; 60(7):431-4. PubMed ID: 3115077
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clot-selective coronary thrombolysis with pro-urokinase.
    Loscalzo J; Wharton TP; Kirshenbaum JM; Levine HJ; Flaherty JT; Topol EJ; Ramaswamy K; Kosowsky BD; Salem DN; Ganz P
    Circulation; 1989 Apr; 79(4):776-82. PubMed ID: 2494004
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New developments in thrombolytic therapy.
    Collen D; Gold HK
    Adv Exp Med Biol; 1990; 281():333-54. PubMed ID: 2129372
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.